GSK 6-K: CEO, CFO acquire Ordinary Shares at £18.1420
Filing Impact
Filing Sentiment
Form Type
6-K
GSK plc reported routine insider share acquisitions by multiple senior executives under its Share Reward Plan. The transactions covered Ordinary Shares of 31 ¼ pence each (ISIN: GB00BN7SWP63) at £18.1420 per share on the London Stock Exchange.
Participants included CEO Emma Walmsley and CFO Julie Brown, each acquiring 14 Ordinary Shares (7 partnership and 7 matching). Other executives—James Ford, Sally Jackson, Regis Simard, Philip Thomson, and Victoria Whyte—also acquired 14 shares each on 2025-11-11. David Redfern acquired 12 shares (6 partnership and 6 matching). These are standard plan-related purchases disclosed via Form 6-K.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of November 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK
plc (the
'Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Emma Walmsley
|
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.1420
|
7 (partnership shares)
|
||
|
£18.1420
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume
Price
|
14 Ordinary Shares
£18.1420
|
||
|
e)
|
Date
of the transaction
|
2025-11-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Julie Brown
|
|
|
b)
|
Position/status
|
Chief
Financial Officer
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.1420
|
7 (partnership shares)
|
||
|
£18.1420
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume
Price
|
14 Ordinary Shares
£18.1420
|
||
|
e)
|
Date
of the transaction
|
2025-11-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
James Ford
|
|
|
b)
|
Position/status
|
SVP and
Group General Counsel, Legal and Compliance
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.1420
|
7 (partnership shares)
|
||
|
£18.1420
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume
Price
|
14 Ordinary Shares
£18.1420
|
||
|
e)
|
Date
of the transaction
|
2025-11-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Sally Jackson
|
|
|
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.1420
|
7 (partnership shares)
|
||
|
£18.1420
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume
Price
|
14 Ordinary Shares
£18.1420
|
||
|
e)
|
Date
of the transaction
|
2025-11-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
David Redfern
|
|
|
b)
|
Position/status
|
President,
Corporate Development
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.1420
|
6 (partnership shares)
|
||
|
£18.1420
|
6 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume
Price
|
12 Ordinary Shares
£18.1420
|
||
|
e)
|
Date
of the transaction
|
2025-11-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Regis Simard
|
|
|
b)
|
Position/status
|
President,
Global Supply Chain
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.1420
|
7 (partnership shares)
|
||
|
£18.1420
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume
Price
|
14 Ordinary Shares
£18.1420
|
||
|
e)
|
Date
of the transaction
|
2025-11-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Philip Thomson
|
|
|
b)
|
Position/status
|
President,
Global Affairs
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.1420
|
7 (partnership shares)
|
||
|
£18.1420
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume
Price
|
14 Ordinary Shares
£18.1420
|
||
|
e)
|
Date
of the transaction
|
2025-11-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Deborah Waterhouse
|
|
|
b)
|
Position/status
|
CEO,
ViiV Healthcare and President, Global Health, GSK
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.1420
|
7 (partnership shares)
|
||
|
£18.1420
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume
Price
|
14 Ordinary Shares
£18.1420
|
||
|
e)
|
Date
of the transaction
|
2025-11-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Victoria Whyte
|
|
|
b)
|
Position/status
|
SVP
& Company Secretary
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.1420
|
7 (partnership shares)
|
||
|
£18.1420
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume
Price
|
14 Ordinary Shares
£18.1420
|
||
|
e)
|
Date
of the transaction
|
2025-11-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: November
13, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
FAQ
What did GSK (GSK) disclose in this 6-K?
GSK disclosed acquisitions of Ordinary Shares by several executives under the Company’s Share Reward Plan at £18.1420 per share on the London Stock Exchange.
Which GSK executives acquired shares and in what amounts?
Emma Walmsley and Julie Brown each acquired 14 shares. James Ford, Sally Jackson, Regis Simard, Philip Thomson, and Victoria Whyte each acquired 14 shares. David Redfern acquired 12 shares.
What was the transaction date and venue for the GSK insider purchases?
All reported acquisitions occurred on 2025-11-11 and were conducted on the London Stock Exchange (XLON).
At what price were the GSK Ordinary Shares acquired?
Each reported acquisition was at £18.1420 per share.
What share plan was used for these GSK insider acquisitions?
The shares were acquired under GSK’s Share Reward Plan, comprising partnership and matching shares.
What class of GSK securities was involved?
Ordinary shares of 31 ¼ pence each, ISIN GB00BN7SWP63.